Latest Healthcare It News

HealthCo Healthcare and Wellness REIT reported a substantial $89.3 million loss for FY25, driven by tenant payment issues and portfolio downsizing, leading to suspended distributions and a debt facility extension.

TALi Digital Limited reported a sharp reduction in losses for FY25 alongside a strategic acquisition of YCDI Education Australia, signaling a pivot towards social-emotional learning. The company also secured nearly $1 million in fresh capital to support its growth ambitions.

WAM Capital Limited reported a robust 22.2% investment portfolio return for FY2025, outperforming key ASX benchmarks and maintaining its full-year dividend at 15.5 cents per share with a 10% yield.

Pro Medicus has delivered a landmark FY25 with soaring revenue and profit, driven by major contract wins and strategic cloud deployments. The company’s expanding North American footprint and AI initiatives set the stage for sustained growth.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

Pro Medicus Limited reports a record-breaking year with $520 million in new contracts and a surge in cloud adoption, setting the stage for continued growth. The company also advances its AI and cardiology offerings, reinforcing its market position.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the fiscal year ending June 30, 2025, signaling steady returns for shareholders.

Pro Medicus Limited has delivered a record-breaking FY2025 with soaring profits and a wave of major US healthcare contracts, setting the stage for continued expansion.

Pro Medicus Limited has reported a robust FY25 with revenue climbing nearly 32% and net profit up 39%, prompting a significant dividend increase.

Argenica Therapeutics has received detailed FDA feedback outlining specific data requirements to lift the clinical hold on its ARG-007 stroke trial in the US, setting a clear path forward for its neuroprotective drug.

Bailador Technology Investments reported a solid FY25 with a 7.8% post-tax portfolio return and a fully franked final dividend of 3.6 cents per share, underpinned by strong growth in private tech investments and strategic realisations.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.